Rob Brierley
LightNews LightNews
banner
robbrierley.bsky.social
Rob Brierley
@robbrierley.bsky.social
1.3K followers 520 following 290 posts
Editor-in-Chief, The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social.

Views my own; reposting ≠ endorsement. #GastroSky #LiverSky #GISky #OncSky
Posts Replies Media Videos
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial

www.thelancet.com/journals/lan...

#GastroSky #MedSky #IBDSky
Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial
Mirikizumab exhibited safety and efficacy in paediatric participants with moderately-to-severely active ulcerative colitis. These results support further evaluation of mirikizumab in the paediatric po...
www.thelancet.com
November 19, 2025 at 8:21 AM
robbrierley.bsky.social
New at The Lancet Digital Health - Development and validation of a machine-learning model to reduce futile procurements in donations after circulatory death in liver transplantation in the USA: a multicentre study

www.thelancet.com/journals/lan...

#LiverSky #MedSky
Development and validation of a machine-learning model to reduce futile procurements in donations after circulatory death in liver transplantation in the USA: a multicentre study
We show that, compared with surgeon predictions and existing risk-prediction tools, our machine-learning model can enhance the accuracy of the prediction of progression to death in DCD donors and redu...
www.thelancet.com
November 18, 2025 at 2:44 PM
robbrierley.bsky.social
New @eClinicalMed - Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis

www.thelancet.com/journals/ecl...

#GastroSky #MedSky #EndoSky
Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis
GLP-1 RAs, particularly Semaglutide and liraglutide, reduce alcohol use as measured by AUDIT scores and show beneficial effects on consumption, relapse, and alcohol-related morbidity. Mechanistic evid...
www.thelancet.com
November 18, 2025 at 2:36 PM
robbrierley.bsky.social
New @eclinicalmed.bsky.social - Preprocedural screening for multidrug-resistant organisms in endoscopic retrograde cholangiopancreatography: an international, multicentre, cross-sectional observational study

www.thelancet.com/journals/ecl...

#GastroSky #MedSky #IDSky #MicroSky
Preprocedural screening for multidrug-resistant organisms in endoscopic retrograde cholangiopancreatography: an international, multicentre, cross-sectional observational study
This study shows global heterogeneity in MDRO carriage among patients undergoing ERCP, reflecting underlying differences in antimicrobial resistance, healthcare infrastructure, and infection control p...
www.thelancet.com
November 18, 2025 at 2:35 PM
robbrierley.bsky.social
New research @eClinicalMed - A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities

www.thelancet.com/journals/ecl...

#GastroSky #MedSky #IBDSky
A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities
Treatment efficacy in similar WH and SA IBD patients recruited to the UK IBD BioResource is unaffected by ethnicity but patients from SA ethnic backgrounds are at increased risk of developing pancreat...
www.thelancet.com
November 18, 2025 at 2:33 PM
Reposted by Rob Brierley
thelancet.com
Liver cancer cases will increase from 0.87 million in 2022 to 1.52 million in 2050.

Join Stephen Lam Chan to explore new strategies to treat liver cancer and how we can advance progress, together.

👉 Register now: hubs.li/Q03GK-q50

#oncology #hepatology #lgcw2025
Blue graphic promoting a Lancet Webinar with text saying: "Join Stephen Lam Chan, Professor at Chinese University of Hong Kong, for our global webinar on the global strategies to reverse the rise of liver cancer on Thursday, November 27, 2025, at 9am GMT/10am CET". A photograph of Stephen Lam Chan appears on the right-side of the graphic. Copyright: Elsevier Ltd.
November 14, 2025 at 5:15 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New @thelancet.com - Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

www.thelancet.com/journals/lan...

#LiverSky #MedSky #EndoSky
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
Pemvidutide treatment met the primary endpoint of MASH resolution without worsening of fibrosis at 24 weeks but did not meet the other primary endpoint of fibrosis improvement without worsening of MAS...
www.thelancet.com
November 12, 2025 at 7:59 AM
Reposted by Rob Brierley
thelancet.com
Liver cancer is the 6th most common cancer globally.

Join our webinar exploring The Lancet's Commission on addressing the global liver cancer burden and its comprehensive strategies from prevention to treatment.

👉 Register: hubs.li/Q03GK-q50

#oncology #hepatology #lgcw2025
Blue graphic promoting a Lancet Webinar. Text saying: "Join Jian Zhou, Professor at Zhongshan Hospital, Fudan University, for our global webinar on global strategies to reverse the rise of liver cancer on Thursday, November 27, 2025 at 9am GMT/10am CET". A photograph of Professor Zhou appears on the right-side of the graphic. Copyright: Elsevier Ltd.
November 12, 2025 at 8:17 AM
Reposted by Rob Brierley
thelancet.com
📣 Big news! We’re excited to announce the Advisory Board for The #LancetSummit: shaping the future of #diabetes prevention. Welcome Amanda Adler, Kamlesh Khunti, Dianna Magliano, Chantal Mathieu and Didac Mauricio Puente. Find out more and submit your abstract to join the Summit: hubs.li/Q03MV20T0
The Lancet Summit: shaping the future of diabetes prevention. Image credit: Ixefra / Getty Images.
November 12, 2025 at 9:03 AM
Reposted by Rob Brierley
thelancet.com
🔔 Introducing The Lancet Regional Health – Africa, a new #goldopenaccess journal promoting the advancement of clinical practice and health policy in Africa.

Explore the new journal: ➡️ spkl.io/63325AbmLD #MedSky
A special preview issue of The Lancet Regional Health – Africa. On the cover is a photograph of a doctor examining a Maasai baby. Copyright: Hugh Sitton/Getty Images.
November 12, 2025 at 11:04 AM
Reposted by Rob Brierley
thelancet.com
What if we could find new ways to approach liver cancer prevention and treatment?

Join Helena Wang on Nov 27 to explore how we can work together to reverse the rise of this global health challenge.

👉 Register now: hubs.li/Q03GK-q50

#oncology #hepatology #lgcw2025
Blue graphic with hexagon pattern. Text says: "The Lancet Webinars. Join Helena Wang, Asia Senior Executive Editor at The Lancet, for our global webinar on global strategies to reverse the rise of liver cancer on Thursday, November 27, 2025 at 9am GMT/10am CET". A photograph of Helena Wang appears on the right-hand side. Copyright: Elsevier Ltd.
November 7, 2025 at 11:10 AM
Reposted by Rob Brierley
eclinicalmed.bsky.social
Incidence of non-colorectal/endometrial malignancies in individuals with #LynchSyndrome: a retrospective cohort study

40% of patients had non-CRC/ECs, with 11% of these cases diagnosed prior to undergoing genetic testing

www.thelancet.com/journals/ecl...
#MedSky
November 5, 2025 at 12:05 PM
Reposted by Rob Brierley
eclinicalmed.bsky.social
⭐New Series on #ChildhoodCancer in Asia now live!

Published collectively with @lancetchildadol.bsky.social, the 3 papers focus on challenges and opportunities for childhood cancer care in #Asia, which has half the global #paediatric #cancer burden

www.thelancet.com/series-do/childhood-cancer-asia
November 6, 2025 at 12:24 PM
Reposted by Rob Brierley
thelancetrheum.bsky.social
NEW RESEARCH—IgG4-related disease in the Japanese population: a whole-genome sequencing study bit.ly/4oVaGPm

Plus, linked Comment bit.ly/4hOOOmz
#Medsky #Rheumsky
November 6, 2025 at 3:42 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
Our December issue is out now at www.thelancet.com/journals/lan...

Content includes diet in GI disorders; IBS; IBD; oesophageal cancer; alcohol-related liver disease; MASLD + more!

#GastroSky #LiverSky #MedSky
November 6, 2025 at 6:57 AM
Reposted by Rob Brierley
thelancet.com
What if we could work together to change the future of liver cancer?

Join our webinar exploring how we can tackle the rising trend of liver cancer and differences in disease management across regions, hosted as part of London Global Cancer Week.

📆 Nov 27, 9am GMT
👉 Register: hubs.li/Q03GK-q50
Blue graphic with text saying: "The Lancet Webinars. Join our global webinar on the global strategies to reverse the rise of liver cancer on Thursday, November 27, 2025 at 9am GMT/10am CET. An image of a red liver in a blue body appears on the right of the graphic in a hexagonal frame. Copyright: Elsevier Ltd.
November 3, 2025 at 3:23 PM
Reposted by Rob Brierley
thelancet.com
Non-coeliac gluten sensitivity (NCGS) remains a highly debated condition, despite ~10% of the global population self-reporting a gluten or wheat sensitivity.

A new Review examines current evidence & provides practical guidance for assessment and management: tinyurl.com/yjafmhc5
Non-coeliac gluten sensitivity
Non-coeliac gluten sensitivity (NCGS) refers to individuals who report intestinal and extraintestinal symptoms related to the ingestion of gluten-based or wheat-based foods, in the absence of coeliac ...
www.thelancet.com
October 30, 2025 at 12:44 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial

www.thelancet.com/journals/lan...

#LiverSky #MedSky
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial
Cilofexor did not significantly reduce the rate of fibrosis progression (vs placebo) in participants with non-cirrhotic PSC. A greater percentage of cilofexor-treated participants had pruritus than pl...
www.thelancet.com
October 29, 2025 at 7:50 AM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

www.thelancet.com/journals/lan...

#LiverSky #MedSky
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Linerixibat significantly improved pruritus versus placebo, supporting its potential to address a major symptom of PBC. An expected increase in diarrhoea in linerixibat-treated patients was observed.
www.thelancet.com
October 29, 2025 at 7:49 AM
Reposted by Rob Brierley
thelancetoncol.bsky.social
🚨Our Nov issue is live - thelancet.com/issue/S1470-...

📊Articles: #breastcancer, #NSCLC, #prostatecancer, #melanoma

📰 Reviews: Tumour-infiltrating lymphocyte therapy in the era of genetic engineering AND AI for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO)
October 28, 2025 at 9:39 AM
Reposted by Rob Brierley
thelancetrheum.bsky.social
Attending #ACR25? Sophie Woolven, Deputy Editor, invites you to reach out with enquiries.

Explore our scope, reach & impact, commitment to publishing excellence, & more: hubs.li/Q03BLchR0 #Medsky #Rheumsky
October 24, 2025 at 3:47 PM
Reposted by Rob Brierley
lancetmicrobe.bsky.social
In advance of our November issue, our latest editorial is now online

The next decade in #AMR: getting the basics right

www.thelancet.com/journals/lan...

#IDSky #ClinMicro #OpenAccess #OA
October 27, 2025 at 10:25 AM
Reposted by Rob Brierley
eclinicalmed.bsky.social
Real-time risk prediction model for sepsis in patients with acute GI bleeds: development and validation of a monitoring tool

This validated model effectively identifies patients with AGIB at high risk of sepsis, addressing an unmet need in emergency care

www.thelancet.com/journals/ecl...
#MedSky
October 27, 2025 at 12:17 PM
Reposted by Rob Brierley
thelancet.com
How does research drive real change?

Our new Lancet- @elsfoundation.bsky.social Evidence to Impact Award is open for proposals!

If your project champions implementation science, health equity, and community engagement, apply now: tinyurl.com/j5dty567
Promotional card for the Lancet-Elsevier Foundation Evidence to Impact Award. Images depict two healthcare workers looking at a clipboard and a person facing into the sun with their eyes closed and holding their hand on their chest.
October 27, 2025 at 2:54 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study

www.thelancet.com/journals/lan...

#GastroSky #MedSky
October 28, 2025 at 7:25 AM